Metabolic reprogramming in lung cancer and its clinical implication
- PMID: 39744129
- PMCID: PMC11688361
- DOI: 10.3389/fphar.2024.1516650
Metabolic reprogramming in lung cancer and its clinical implication
Abstract
Lung cancer has posed a significant challenge to global health, and related study has been a hot topic in oncology. This article focuses on metabolic reprogramming of lung cancer cells, a process to adapt to energy demands and biosynthetic needs, supporting the proliferation and development of tumor cells. In this study, the latest studies on lung cancer tumor metabolism were reviewed, including the impact of metabolic products and metabolic enzymes on the occurrence and development of lung cancer, as well as the progress in the field of lung cancer treatment targeting relevant metabolic pathways. This provides some promising potential directions into exploring lung cancer tumor metabolism and helps researchers to better understand lung cancer.
Keywords: amino acid metabolism; glucose; lipid metabolism; lung cancer; metabolic reprogramming.
Copyright © 2024 Huang, Fan, Gong, Ren, Chen and Xie.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures





Similar articles
-
Tumor metabolic reprogramming in lung cancer progression.Oncol Lett. 2022 Jun 28;24(2):287. doi: 10.3892/ol.2022.13407. eCollection 2022 Aug. Oncol Lett. 2022. PMID: 35814833 Free PMC article. Review.
-
Potential Therapies Targeting the Metabolic Reprogramming of Diabetes-Associated Breast Cancer.J Pers Med. 2023 Jan 14;13(1):157. doi: 10.3390/jpm13010157. J Pers Med. 2023. PMID: 36675817 Free PMC article. Review.
-
Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications.Cancer Lett. 2024 Aug 10;597:217076. doi: 10.1016/j.canlet.2024.217076. Epub 2024 Jun 19. Cancer Lett. 2024. PMID: 38906524 Review.
-
Glutamine metabolism in breast cancer and possible therapeutic targets.Biochem Pharmacol. 2023 Apr;210:115464. doi: 10.1016/j.bcp.2023.115464. Epub 2023 Feb 26. Biochem Pharmacol. 2023. PMID: 36849062 Review.
-
Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects.Front Immunol. 2025 Jan 24;16:1524801. doi: 10.3389/fimmu.2025.1524801. eCollection 2025. Front Immunol. 2025. PMID: 39925801 Free PMC article. Review.
Cited by
-
Metabolic reprogramming signature predicts prognosis and immune landscape in small cell lung cancer: MOCS2 validation and implications for personalized therapy.Front Mol Biosci. 2025 May 16;12:1592888. doi: 10.3389/fmolb.2025.1592888. eCollection 2025. Front Mol Biosci. 2025. PMID: 40452920 Free PMC article.
-
Caspase-independent cell death in lung cancer: from mechanisms to clinical applications.Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 21. doi: 10.1007/s00210-025-04149-0. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40257494 Review.
-
Lipid metabolism reprogramming in chronic obstructive pulmonary disease.Mol Med. 2025 Apr 7;31(1):129. doi: 10.1186/s10020-025-01191-9. Mol Med. 2025. PMID: 40197131 Free PMC article. Review.
-
Silencing PPA1 promotes the survival of non-small cell lung cancer A549 cells under glucose-starved conditions.Transl Cancer Res. 2025 Jun 30;14(6):3785-3796. doi: 10.21037/tcr-2025-1106. Epub 2025 Jun 27. Transl Cancer Res. 2025. PMID: 40687229 Free PMC article.
References
-
- Ao Y.-Q., Gao J., Zhang L.-X., Deng J., Wang S., Lin M., et al. (2023). Tumor-infiltrating CD36+CD8+T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer. BMC Cancer 23, 367. 10.1186/s12885-023-10836-z - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources